Cooley Advises on Candid Therapeutics' $370M Capital Raise, Three-Way Merger
September 11, 2024
September 11, 2024
PALO ALTO, California, Sept. 11 -- Cooley, a law firm, issued the following news release:
San Diego - September 9, 2024 - Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.
The financing was co-led by Venrock Healthcare Capital Partners, Fairmount, TCGX and venBio Partners. Other no . . .
San Diego - September 9, 2024 - Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.
The financing was co-led by Venrock Healthcare Capital Partners, Fairmount, TCGX and venBio Partners. Other no . . .